Controlled Clinical Trial Evaluating the Efficacy of Microneedling Combined with Exosomes Versus Microneedling Alone in the Treatment of Melasma

Melasma is a chronic pigmentary disorder that presents significant
therapeutic challenges due to its recurrent nature and variable
response to conventional treatments. It predominantly affects
photoexposed facial areas and often impacts patient’s quality
of life. Microneedling is an established technique for melasma
management, promoting skin renewal and enhancing the
transdermal delivery of depigmenting agents. Recently, exosomes
have emerged as a novel therapeutic approach with regenerative
and pigment-modulating potential.
This pilot randomized controlled clinical trial aimed to assess the
efficacy and safety of microneedling combined with topical exosomes
compared to microneedling alone in the treatment of melasma.
Twelve female participants were randomized into two groups: one
treated with microneedling and topical application of exosomes,
the other with microneedling and saline solution as control group.
Outcomes were evaluated through clinical assessment using MASI
and GAIS scales.
The combination group showed greater reduction in melasma
severity and improved aesthetic appearance than the control group.
No adverse effects were reported. These findings suggest that
exosomes may enhance the therapeutic efficacy of microneedling.
This approach represents a promising and safe alternative for
melasma management and supports further investigation into
exosome-based dermatological therapies.